| Industry | Estimated fit |
|---|---|
| Healthcare & BiotechMatches your industry (clinical) | 81 |
| Technology & SoftwareMatches your industry (technology, tech) | 78 |
| Environment & ConservationMatches your industry (environment) | 73 |
| Transportation & LogisticsMatches your industry (transit) | 59 |
| Agriculture & FarmingLimit: Not clearly about your industry or what you need funding for; check the… | 54 |
| Arts & CultureLimit: Nothing in this notice points to arts & culture | 54 |
| Industry | Estimated fit |
|---|---|
| Education & TrainingLimit: Nothing in this notice points to education & training | 54 |
| Energy & Clean TechLimit: Nothing in this notice points to energy & clean tech | 54 |
| Finance & BankingLimit: Nothing in this notice points to finance & banking | 54 |
| Housing & Real EstateLimit: Nothing in this notice points to housing & real estate | 54 |
| ManufacturingLimit: Nothing in this notice points to manufacturing | 54 |
| Retail & E-CommerceLimit: Nothing in this notice points to retail & e-commerce | 54 |
| Social Services & NonprofitLimit: Nothing in this notice points to social services & nonprofit | 54 |
| Food & BeverageLimit: Nothing in this notice points to food & beverage | 52 |
| Construction & InfrastructureLimit: Nothing in this notice points to construction & infrastructure | 48 |
These are our matcher’s estimates for a typical business in each industry. A real match depends on your size, your state and what you need the money for — check your own fit.
NIH program to develop or adapt innovative senescence technologies (SenTecs) for identifying, characterizing, and modulating senescent cells in aging and disease. Five-year, two-phase milestone-driven awards (UG3 feasibility then UH3 validation). Eligible applicants include small businesses, other for-profits, nonprofits, universities, and state, local, tribal, and federal entities.
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit the development of innovative senescence technologies (SenTecs), or the adaptation of existing technologies focused on identification, characterization and understanding the biological consequences of senescent cell (SnC) heterogeneity in the context of the tissue environments and secretomes to facilitate novel strategies for modulating SnCs in vivo and for predicting the outcomes of targeting SnCs in human aging and in disease conditions. These are five-year, milestone-driven awards consisting of two phases. The first two years constitute the UG3 phase and are focused on SenTec development and demonstration of technology feasibility. The following 3-years is the SenTec application UH3 phase where SenTecs continue to be optimized, refined and validated. In the final year of the UH3 award, SenTecs will undertake a demonstration project conducted in a collaborative effort within SenNet to provide further validation of the proposed SenTec. Applicants are required to submit both UG3 and UH3 projects together when responding to this NOFO. Transition from the UG3 to UH3 phases is not automatic and will occur only after administrative review of each SenTec at the close of Year 2 of the award.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Topics
Open opportunities funding similar work, from the same funder or in the same place.
NIH BRAIN Initiative grants to develop tools and computational models for high-resolution, synchronous measurement of complex behaviors alongside neural activity in humans and other species. Eligible applicants include…
NIH/NCI K99/R00 career-development award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent tenure-track faculty positions; requires the candidate to lead an…
NIH/NCI UH3 cooperative agreement to clinically validate established molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, or treatment response using specimens from…
NIH/NCI K99/R00 award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent faculty careers. The applicant is typically the sponsoring institution; eligible…
NIH/NCI cooperative agreement (UH2/UH3) funding validation of molecular, cellular, and imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response. Open to universities,…
NIH/NCI program funding revision applications to adapt and clinically validate molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response prediction.…